These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35832692)

  • 1. Cost-effectiveness analysis of COVID-19 vaccination in Poland.
    Orlewska K; Wierzba W; Śliwczynski A
    Arch Med Sci; 2022; 18(4):1021-1030. PubMed ID: 35832692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.
    Grzesiowski P; Aguiar-Ibáñez R; Kobryń A; Durand L; Puig PE
    Hum Vaccin Immunother; 2012 Oct; 8(10):1382-94. PubMed ID: 23095867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.
    Atherly AJ; van den Broek-Altenburg EM
    BMC Health Serv Res; 2023 Apr; 23(1):372. PubMed ID: 37072753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden.
    Wolff E; Storsaeter J; Örtqvist Å; Naucler P; Larsson S; Lepp T; Roth A
    Vaccine; 2020 Jul; 38(32):4988-4995. PubMed ID: 32536548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
    BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.